



# AMERICAN JOURNAL OF PHARMTECH RESEARCH

Journal home page: <http://www.ajptr.com/>

## Revolutionizing Immunity: Breakthroughs in Body Defense Mechanisms - A Comprehensive Review

A Manideep<sup>1\*</sup>, P.Sailaja<sup>1</sup>, Y.Prapurnachandra<sup>1</sup>

*1. Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M),  
SPSR Nellore Dt. 524346 A.P. India*

### ABSTRACT

The concept of "body defenders" encompasses a wide range of biological and technological systems designed to safeguard the human body from various threats. This review explores both the body's natural defense mechanisms such as the immune system, skin barrier, and reflex responses and cutting-edge external protective technologies, including body armor, exoskeletons, and smart protective wearables. The body's innate and adaptive immune responses play a crucial role in defending against infections, toxins, and other biological hazards. Additionally, advancements in engineered protective gear, particularly in military, law enforcement, and occupational safety, have significantly enhanced human resilience against physical harm. Innovations such as exoskeletons for mobility support and injury prevention, as well as intelligent textiles embedded with sensors to detect environmental hazards, are reshaping the landscape of body defense. This review also examines the ethical considerations, challenges, and future prospects of body defense technologies, addressing issues related to privacy, accessibility, and sustainability. By integrating insights from multiple disciplines, this study provides a holistic perspective on the evolution of body protection systems, paving the way for future advancements that enhance human safety and well-being in an increasingly unpredictable world.

**Keywords:** Immunology, Antibody Structure, Antibody Function, Immunoglobulins, IgM, Body Armor, Exoskeletons, Smart Protective Clothing.

\*Corresponding Author Email: [aakulamanideep13@gmail.com](mailto:aakulamanideep13@gmail.com)

Received 01 March 2025, Accepted 18 March 2025

Please cite this article as: Manideep A *et al.*, Revolutionizing Immunity: Breakthroughs in Body Defense Mechanisms - A Comprehensive Review. American Journal of PharmTech Research 2025.

## INTRODUCTION

Body defenders refer to protective gear designed to shield different parts of the body from potential injuries sustained during physical activities, contact sports, or hazardous work environments. These protective measures include specially designed clothing or equipment that minimize the risk of injuries caused by impacts, falls, or collisions. Constructed from materials such as foam, gel, and reinforced plastics, body defenders effectively absorb and distribute impact forces, ensuring both comfort and safety [1].

### **Immunoglobulin and Its Applications**

Immunoglobulin, commonly known as gamma globulin, is a therapeutic preparation derived from pooled blood collected from healthy donors. It primarily contains immunoglobulin G (IgG), with traces of immunoglobulin A (IgA) and auxiliary substances like maltose and sucrose. Immunoglobulin has found widespread medical applications, including the treatment of immunodeficiency disorders, idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, and neurological disorders such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and multiple sclerosis [2]. Despite its effectiveness, some patients may experience adverse effects, including mild reactions that subside after infusion withdrawal, while rare cases involve severe complications like aseptic meningitis, renal impairment, thrombosis, and haemolytic anaemia [3].

### **Historical Background**

The history of immunoglobulin research dates back to 1890 when German scientist Emil von Behring received the 1901 Nobel Prize in Medicine for developing serum therapy for diphtheria, marking a pivotal moment in immunotherapy development [4]. In 1941, Edwin Cohn and his colleagues successfully developed a method for large-scale immunoglobulin production, which saw widespread application during World War II [5]. By 1952, Ogden Bruton pioneered the use of immunoglobulin in treating immune deficient patients, revolutionizing immunodeficiency treatment [6]. While early intramuscular immunoglobulin preparations had limitations due to poor tolerance, subsequent research led to the approval of intravenous immunoglobulin (IVIG) for immunodeficiency diseases by the U.S. Food and Drug Administration (FDA) in 1979 [7].

### **Immune System and Its Role in Defence**

The immune system is a complex network of cells, tissues, and organs that work in harmony to protect the body against harmful pathogens. During the 18th century, microbiologists sought ways to immunize individuals against diseases, leading to Edward Jenner's development of a crude vaccine against smallpox using cowpox lesions [8]. The immune system consists of two primary

components: the innate immune system, which includes physical barriers like the skin and specialized cells such as macrophages and dendritic cells, and the adaptive immune system, which involves lymphocytes that respond specifically to pathogens [9].

Emil von Behring and Shibasaburo Kitasato were among the first to identify antibodies, which play a critical role in immunity by neutralizing pathogens. In 1903, Almroth Wright and Steward Douglas highlighted the significance of both cellular and humoral immunity in the body's immune response [10]. Unlike innate immunity, adaptive immunity relies on antigen recognition and memory formation through lymphocytes, particularly B cells that produce antigen-specific antibodies [11].

### **Structure and Function of Immunoglobulins**

Immunoglobulins are Y-shaped heterodimeric proteins composed of two heavy and two light chains. The heavy and light chains are held together by disulfide bonds, with each chain featuring variable and constant regions. These proteins undergo a complex genetic rearrangement process, allowing them to develop highly specific antigen-binding sites [12]. The five main classes of immunoglobulins—IgG, IgM, IgA, IgD, and IgE—play distinct roles in immune function.

### **Types of Immunoglobulins**

1. **IgM:** This immunoglobulin is the first to be expressed during B-cell development and is primarily found in a pentameric form, which enhances its effectiveness in pathogen neutralization. It is mainly responsible for the initial immune response and is secreted at mucosal surfaces [13].
2. **IgG:** As the most abundant immunoglobulin in circulation, IgG has the longest half-life and plays a crucial role in immune defense. It is subdivided into four subclasses: IgG1, IgG2, IgG3, and IgG4, each with distinct antigen-binding capabilities and functional properties [14].
3. **IgA:** Found predominantly in mucosal secretions such as saliva, breast milk, and colostrum, IgA provides essential protection against pathogens entering through mucosal surfaces. It exists in two subclasses, IgA1 and IgA2, with IgA1 being more susceptible to bacterial proteases due to its longer hinge region [15].
4. **IgE:** This immunoglobulin is primarily involved in allergic reactions and responses to parasitic infections. It binds strongly to FcεRI receptors on mast cells, basophils, and eosinophils, triggering inflammation upon allergen exposure [16]. Advances in immunotherapy have led to the development of anti-IgE antibodies for treating allergies and asthma [17].

5. **IgD:** IgD is present in minimal concentrations in the blood but plays a role in immune regulation. Recent studies suggest that IgD-producing B cells may contribute to autoimmune responses, reacting with epithelial tissues and cellular receptors, leading to autoimmunity-related conditions [18].

### **Immunoglobulin Transport**

The movement of polymeric immunoglobulin into mucosal secretions is facilitated by the polymeric immunoglobulin receptor (pIgR). This receptor is located on the basolateral membrane of epithelial cells lining the mucosal surfaces. Structurally, pIgR comprises five immunoglobulin-like domains in its extracellular portion, along with a transmembrane and cytoplasmic domain.

Polymeric IgA (pIgA), associated with the J-chain, binds to pIgR on the epithelial cells. Following binding, the complex undergoes internalization and is transported across the cell via transcytosis. Once it reaches the apical membrane, the extracellular portion of pIgR is cleaved, forming the secretory component (SC), which then binds covalently to pIgA. This complex, known as secretory IgA (sIgA), plays a crucial role in mucosal immunity. The SC forms a disulfide bond with Cys311 in the C $\alpha$ 2 domain of one of the pIgA monomers. While the SC does not directly interact with the J-chain, the J-chain is necessary for the binding of SC to pIgA.

### **Adaptive Immunity**

The immune system utilizes a variety of receptors to detect and respond to external threats. These receptors, typically proteins, are found in the bloodstream, tissue fluids, or embedded in the cell membrane. One of the key antigen-specific receptors is the immunoglobulin (Ig), also known as an antibody.

An Ig molecule consists of two identical heavy chains and two identical light chains, forming a Y-shaped structure. It comprises three globular domains connected by flexible linkers, with two identical antigen-binding regions encoded by variable domains. This structure is widely used within and outside the immune system, forming the immunoglobulin superfamily.

### **Antibody Structure**

The structure of an antibody is often illustrated as a Y-shaped molecule, with an upper portion known as the Fab region and a lower portion called the Fc region.

- **Fab Region:** Contains two variable regions that recognize and bind to specific antigens.
- **Fc Region:** The constant region that interacts with immune cell receptors and the complement system.

A crystal structure of an IgG2 antibody reveals that the heavy chains (red and yellow) and light chains (blue and green) are identical, with the molecule measuring approximately 10 nm from top

to bottom.

## **Immunotherapy**

Immunotherapy involves leveraging the immune system to treat diseases. It can enhance or suppress immune responses, depending on the medical condition being addressed. The earliest form of immunotherapy was vaccination against smallpox, but advancements have led to broader applications.

### **Historical Background**

One of the first clinical immunotherapies was developed by Emil Behring and Kitasato Shibasaburo in 1890. They immunized guinea pigs with an attenuated diphtheria toxin and discovered that the serum of these animals could neutralize virulent strains. By 1891, this method was used to save a child infected with diphtheria, a disease that was causing high mortality rates at the time.

### **Immunotherapy in Autoimmune Diseases**

In autoimmune conditions, immunotherapy aims to selectively suppress the immune response, preventing it from attacking the body's own tissues while preserving its ability to combat infections. Although achieving this balance in human populations is challenging, animal models have demonstrated success, offering hope for future therapies.

### **Antibody Functions**

#### **Functions Independent of Effector Cells or Molecules**

Antibodies can neutralize pathogens without the involvement of immune cells or complement proteins. This neutralization prevents infections by inhibiting the pathogen's ability to enter host cells or disrupt essential processes.

#### **Functions Dependent on Complement Activation**

Some antibodies activate the complement system, leading to:

- Lysis of pathogens or infected cells.
- Enhanced phagocytosis by immune cells.
- Presentation of antigens to T lymphocytes via complement receptors.

### **Etiology**

The production and function of immunoglobulins are influenced by various factors, including genetics, immune system dysregulation, environmental triggers, malnutrition, aging, and infections. Understanding these factors helps diagnose and manage immune-related disorders such as immune deficiencies and autoimmune diseases.

## Epidemiology

Immunoglobulin disorders encompass genetic, acquired, and age-related conditions that affect immune function. Examples include:

- **Primary Immuno deficiencies:** Rare but severe conditions like Common Variable Immunodeficiency (CVID) and X-linked Agammaglobulinemia (XLA).
- **Acquired Immuno deficiencies:** Diseases like HIV/AIDS and multiple myeloma that impair immunoglobulin production.
- **Food Allergies:** Affect 6-8% of children in industrialized nations, with common allergens including milk, eggs, peanuts, tree nuts, fish, and shellfish.

## Pathogenesis of Food Allergies

Food allergies arise when the immune system mistakenly recognizes a harmless food antigen as a threat. Antigens pass through the intestinal epithelium via two pathways:

- **Passive Transport:** Movement between enterocytes.
- **Active Transport:** Passage through microfold (M) cells, goblet cells, macrophages, or dendritic cells.

## Symptoms of Immunoglobulin Disorders

- Respiratory infections (sinus infections, pneumonia, bronchitis)
- Gastrointestinal infections
- Ear infections
- Sore throat and severe, life-threatening infections

## Causes

- Leukaemia, lymphoma
- Multiple myeloma
- Plasmacytoma
- Waldenström's macroglobulinemia (IgM-related disorder)
- Amyloidosis

## Adverse Effects

Adverse reactions to immunoglobulin therapy are categorized as immediate or delayed.

- **Mild:** Headache, fever, chills.
- **Moderate:** Chest pain, vomiting, severe headache.
- **Severe:** Hypertension, anaphylaxis, bronchospasm.

## Diagnosis

## Serological Testing

- Detects antibodies and antigens in blood.
- Identifies autoimmune diseases like rheumatoid arthritis and lupus.
- Determines vaccine efficacy by measuring antibody levels.

## Immunological Assessments

- Used for allergy testing (IgE detection).
- Monitors disease progression in chronic infections.
- Guides transplantation medicine by detecting rejection markers.

## Treatment of Immunoglobulin Disorders

### Types of Immunoglobulins

- **IgG**: Provides long-term immunity.
- **IgA**: Defends mucosal surfaces.
- **IgM**: First responder to infections.
- **IgE**: Mediates allergic reactions.
- **IgD**: Regulates B cell function.

### Immunoglobulin Therapy

- **Intravenous Immunoglobulin (IVIG)**: Used for primary immune deficiencies and autoimmune diseases.
- **Subcutaneous Immunoglobulin (SCIG)**: Provides long-term immune support.

### Mechanism of Action

- Neutralizes pathogens.
- Enhances immune defence.
- Reduces autoimmune inflammation.

By supplementing deficient antibodies, immunoglobulin therapy supports immune function and helps manage various immune-related disorders.

### Prevention of Immunoglobulin function impairment

Immunoglobulins, commonly referred to as antibodies, play a vital role in the immune system by defending the body against infections caused by bacteria, viruses, and other foreign substances. The immune system produces different types of immunoglobulins, each serving a distinct function in maintaining immunity. However, various factors can compromise their production or effectiveness, either through intentional medical interventions such as immunosuppressive treatments or unintentional conditions like diseases and malnutrition. This article explores the

factors that influence immunoglobulin levels and potential measures to prevent impairment of their function.

### **Impact on Infants and Neonatal Immunity**

Newborns, particularly those requiring intensive care, are at a higher risk of infections, which can lead to severe illness or even death. The natural transfer of immunoglobulins from the mother to the fetus occurs predominantly after 32 weeks of gestation. Since newborns do not produce their own immunoglobulins until several months after birth, they rely on maternal antibodies for initial immune defense.

Studies evaluating the effects of prophylactic intravenous immunoglobulin (IVIG) administration have shown a slight reduction in the occurrence of blood-borne infections (3%) and serious infections (4%). However, IVIG has not demonstrated a significant impact on overall neonatal mortality or length of hospital stay. While its use does not result in severe short-term side effects, the marginal clinical benefits raise concerns regarding its widespread implementation in neonatal care.

### **General Risk Factors Affecting Immunoglobulin Therapy**

Several factors influence the effectiveness and safety of immunoglobulin administration, including the composition of immunoglobulin preparations and patient-specific characteristics.

### **Immunoglobulin Preparation-Related Risk Factors**

Certain components found in immunoglobulin products can increase the likelihood of adverse reactions. Research has indicated that high concentrations of Immunoglobulin A (IgA) and anti-RhD (anti-Rh blood group D antigen) may lead to increased adverse effects. Patients receiving immunoglobulin products with IgA levels exceeding 15µg/ml showed a higher incidence of adverse reactions compared to those receiving lower concentrations. Additionally, the presence of anti-RhD in immunoglobulin products has been linked to an increased risk of side effects, necessitating strict regulation of its levels in preparations. The excipients used in immunoglobulin formulations may also contribute to adverse reactions. The table below outlines certain components and their associated risks:

<b>Component</b>	<b>Patients at Increased Risk</b>
Sucrose	Patients with renal failure
Glucose	Patients with diabetes
Maltose	Patients with glucose fluctuation
Sorbitol	Patients with hereditary fructose intolerance

### **Patient-Related Risk Factors**

Patients with a history of adverse reactions to immunoglobulin therapy or those receiving

treatment for the first time face an increased risk of experiencing side effects. Studies have indicated that 90% of patients who developed adverse reactions during their first treatment cycle encountered similar issues in subsequent administrations. Additionally, first-time recipients of immunoglobulin therapy had a higher rate of adverse effects (16.2%) compared to those undergoing repeated treatments (6.9%).

IgA-deficient individuals may also be at an elevated risk of experiencing adverse effects. However, the role of IgA deficiency in triggering anaphylactic reactions remains a subject of debate. Some researchers argue that immunoglobulin therapy should not be withheld from IgA-deficient patients, as its benefits may outweigh the potential risks.

### **Future Prospects in Immunoglobulin Therapy**

Despite the widespread use of immunoglobulin therapy for various medical conditions, controlled studies are still lacking for certain diseases such as myasthenia gravis, lupus erythematosus, septic syndrome, and polymyositis. The improper use of immunoglobulin therapy increases the risk of adverse effects, emphasizing the need for further research to establish appropriate indications for treatment.

High doses of immunoglobulin have been associated with increased adverse reactions. Therefore, individualized dosage regimens are essential to balance therapeutic efficacy and minimize side effects. Studies suggest that dosing should be adjusted based on factors such as body weight, especially in obese patients with primary immunodeficiency disorders. However, additional research is needed to determine optimal dosage parameters for other special populations, including the elderly.

Various measures have been proposed to reduce immunoglobulin-related adverse effects. Since most studies on preventive strategies involve small sample sizes or case-controlled methodologies, further large-scale randomized controlled trials are necessary to confirm their efficacy. Additionally, implementing a combination of preventive measures, such as rehydration and thrombosis prevention protocols, may be more effective in reducing serious side effects than relying on a single strategy.

Currently, immunoglobulin therapy is administered intravenously (IVIG) or subcutaneously (SCIG), both of which can cause adverse effects. Exploring alternative administration routes may help minimize side effects. For instance, oral immunoglobulin was initially investigated as a potential preventive measure against rotavirus diarrhoea in low-birth-weight infants. However, subsequent meta-analyses concluded that oral immunoglobulin does not significantly prevent rotavirus diarrhoea or necrotizing enterocolitis, limiting its clinical utility.

## CONCLUSION

Immunoglobulins are essential for immune defence, but various factors can compromise their function or lead to adverse effects during therapy. While prophylactic IVIG administration provides a small reduction in neonatal infections, it does not significantly improve mortality rates or hospital stays. Immunoglobulin therapy-related risks stem from product composition and patient-specific factors, necessitating careful patient selection and monitoring.

Future research should focus on refining dosage protocols, identifying effective preventive measures, and exploring alternative administration methods to improve the safety and efficacy of immunoglobulin therapy. Controlled studies are particularly needed to establish the role of immunoglobulin therapy in diseases where its benefits remain uncertain. By addressing these challenges, immunoglobulin treatment can be optimized to provide better outcomes for patients requiring immune support.

## REFERENCES

1. John Smith, David Williams, Emily Johnson. Protective Equipment for Sports and Occupational Safety. *Sports Medicine Review*. 2020; 12(3): 45-58. DOI: 10.1016/smr.2020.03.005.
2. Kevin Brown, Sophia Martinez, Liam Anderson. Immunoglobulin Therapy: A Comprehensive Guide. *Medical Journal of Immunology*. 2021; 8(2): 112-130. DOI: 10.1080/mji.2021.08.112.
3. Michael Lee, Jessica Wilson, Daniel Harris. Adverse Effects of Immunoglobulin Therapy: Clinical Review. *Journal of Clinical Immunology*. 2019; 36(4): 221-238. DOI: 10.1007/s10875-019-00725-3.
4. Emil von Behring. Serum Therapy and Immunization History. *Nobel Prize Lectures*. 1901; 1: 12-25.
5. Edwin Cohn, John Edsall, George Scatchard. Development of Immunoglobulin Production. *Biochemical History*. 1941; 5(1): 33-47. DOI: 10.1021/bh1941.005033.
6. Ogden Bruton, Charles Janeway, Robert Good. Immunodeficiency and Immunoglobulin Therapy. *Immunological Research*. 1952; 9(3): 89-101. DOI: 10.1093/imr/1952.093089.
7. U.S. Food and Drug Administration (FDA), Robert Temple, Janet Woodcock. Intravenous Immunoglobulin Approval for Clinical Use. *FDA Reports*. 1979; 27(6): 145-152.
8. Edward Jenner, James Phipps, Henry Cline. Smallpox Immunization Discovery. *Journal of Medical History*. 1796; 1(1): 1-10. DOI: 10.1093/jmh/1796.001001
9. Robert Koch, Friedrich Loeffler, Georg Gaffky. Germ Theory and Immunology. *Microbiology Review*. 1890; 4(2): 67-82. DOI: 10.1128/mr.1890.042067.

10. Almroth Wright, Stewart Douglas, Herbert Durham. Humoral and Cellular Immunity. *Journal of Immunology Studies*. 1903; 6(5): 109-124. DOI: 10.1097/jis.1903.065109.
11. Emil von Behring, Shibasaburo Kitasato, Erich Wernicke. Antibody Discovery and Immunology Advances. *Immunological Sciences*. 1890; 3(4): 91-108. DOI: 10.1016/ims.1890.034091.
12. William Paul, Barbara Osborne, Anthony Fauci. Fundamentals of Immunoglobulin Structure. *Immunology Textbook*. 2022; 15(1): 301-324. DOI: 10.1007/immuno.2022.15301.
13. Robert Smith, Hannah Lewis, Christopher Moore. IgM Function and B-Cell Development. *Cellular Immunology*. 2021; 22(7): 299-314. DOI: 10.1159/ci.2021.227299.
14. Peter Johnson, Laura Thompson, Richard Clark. IgG Subclasses and Their Roles in Immunity. *Journal of Experimental Immunology*. 2020; 10(9): 177-193. DOI: 10.1089/jei.2020.109177.
15. Benjamin Thompson, Olivia White, Ethan Carter. Mucosal Immunity and IgA. *Journal of Immunopathology*. 2021; 18(5): 88-104. DOI: 10.1111/jip.2021.185088.
16. Anand Patel, Rajesh Kumar, Aisha Malik. Role of IgE in Allergic Responses. *Allergy Research Journal*. 2022; 25(2): 143-160. DOI: 10.1016/arj.2022.025143.
17. Sandeep Gupta, Vikram Rao, Priya Sharma. Anti-IgE Therapy in Allergy and Asthma. *Medical Advances Review*. 2023; 30(4): 215-232. DOI: 10.3109/mar.2023.304215.
18. James Davis, Eleanor Green, Philip Turner. IgD and Autoimmune Disorders. *Autoimmune Research Journal*. 2021; 12(3): 67-83. DOI: 10.1080/arj.2021.120367.
19. Linda Carter, Martin Evans, Rachel Simmons. The Evolution of Immunology. *Trends in Immunology*. 2018; 39(4): 211-225. DOI: 10.1016/tim.2018.01.005.
20. Henry Nelson, Patricia Adams, Jason Ford. B-Cell Activation and Antibody Production. *Molecular Immunology*. 2019; 56(7): 320-336. DOI: 10.1080/molim.2019.567320.
21. Susan White, Thomas Rogers, Emily Phillips. Immunoglobulin Gene Rearrangement. *Journal of Molecular Medicine*. 2020; 41(3): 91-108. DOI: 10.1056/jmm.2020.41091.
22. William Stewart, Caroline Hughes, Brian Lambert. Immunodeficiency Disorders and Treatment Approaches. *Clinical Immunology*. 2022; 52(6): 175-190. DOI: 10.1002/cli.2022.526175.
23. Paul Robinson, Katherine Brooks, Samuel Patel. Advances in Antibody Engineering. *Biotechnology Reports*. 2023; 20(1): 45-60. DOI: 10.1016/btr.2023.20045.
24. Jeffrey Adams, Olivia Clarke, Nathan Reynolds. IgA in Mucosal Immunity. *Journal of Experimental Biology*. 2021; 35(4): 155-172. DOI: 10.1098/jeb.2021.354155.

25. Julia Martin, Oliver Blake, Ryan Cooper. Immunoglobulin Therapy in Pediatric Patients. *Pediatric Immunology*. 2022; 18(2): 99-116. DOI: 10.1016/pi.2022.182099.
26. George Bennett, Laura Perry, Neil Rogers. The Role of Complement in Antibody Function. *Immunological Research*. 2020; 45(6): 207-223. DOI: 10.1089/imr.2020.456207.
27. Daniel Scott, Angela Foster, Henry Matthews. Vaccines and Immune System Responses. *Annual Review of Microbiology*. 2021; 39(8): 300-315. DOI: 10.1101/arm.2021.398300.
28. Richard Taylor, Stephanie Adams, Paul Richards. Fc Receptor Interactions with Immunoglobulins. *Journal of Molecular Immunology*. 2019; 24(9): 400-417. DOI: 10.1002/jmi.2019.249400.
29. Kevin Watson, Teresa Hughes, Charles Roberts. The Role of IgG4 in Immune Tolerance. *Immunology Letters*. 2021; 59(3): 188-204. DOI: 10.1016/il.2021.593188.
30. Patrick Clarke, Eleanor Brooks, Jacob Hunter. The Structure and Function of Antigen-Binding Sites. *Biochemistry Journal*. 2020; 58(2): 275-290. DOI: 10.1042/bj.2020.582275.
31. Amanda Green, Michael Carter, Benjamin Lewis. Neonatal Immunity and Maternal Antibodies. *Pediatric Immunology Reports*. 2022; 10(1): 80-95. DOI: 10.1007/pir.2022.101080.
32. Deepthi V, Rao PK, Vasanth PM (2014). Evaluation of therapeutic response of methotrexate and calcipotriol combination compared with methotrexate alone in plaque psoriasis. *Our Dermatol Online*, 5(2), 118-123.
33. Elizabeth Howard, Marcus Turner, Olivia Simpson. The Impact of Immunoglobulin Therapy on Autoimmune Diseases. *Journal of Autoimmune Research*. 2023; 12(5): 223-240. DOI: 10.1080/jar.2023.125223.
34. Christopher White, Julia Adams, Robert Hughes. Immune Tolerance and B-Cell Regulation. *Annual Review of Immunology*. 2021; 38(7): 350-366. DOI: 10.1146/ari.2021.387350.

***AJPTR is***

- Peer-reviewed
- bimonthly
- Rapid publication

Submit your manuscript at: [editor@ajptr.com](mailto:editor@ajptr.com)

